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HLA-DR15, Reduced
Relapse Rate and
Improved Survival after
HLA Identical Sibling
Hemopoietic
Stem Cell
Transplantation
Dr. Martin Stern and colleagues (November 2006,
p. 1169) described a decreased risk of relapse and
improved survival after hematopoietic stem cell trans-
plantation (HSCT) in human leukocyte antigen
(HLA)-DR15-positive recipients. We have analyzed
outcome data from HSCT in HLA identical related
transplants performed in 3 Manchester centers be-
tween April 1996 and December 2005, and have con-
ﬁrmed this observation. All patients and their donors
were typed for all HLA loci using molecular-based
methodologies. No signiﬁcant differences between
the clinical characteristics of our patients and those
reported by Dr. Stern and Colleagues were identiﬁed.
A total of 286 HLA identical related transplants were
performed at these 3 centers during this period. Anal-
ysis of the adults (ages 17–66 years; n  211) showed
an improved overall survival in DR15-positive recip-
ients; P  .0143 (Figure 1).
Recipients with acute graft-versus-host disease
show improved survival if DR15 positive (P  .0196);
this is also the case in those with survival of100 days
(P  .03). Dr. Stern and colleagues suggest that this
effect may result from a lower relapse rate as a result
of an improved immune response in DR15-positive
individuals. To investigate this further, we repeated
the analysis in 133 (88 adult; 45 pediatric) transplants
using unrelated donors HLA identical at allele level
for HLA-A, B, Cw, DRB1, and DQB1. If the presence
of HLA-DR15 reduces the relapse rate, a similar trend
should be observed in these extremely well-matched
unrelated transplants. Interestingly, the adult recipients
of unrelated transplants (n  88) had reduced overall
survival if DR15 positive, with DR15-negative recipients
showing improved survival; P  .0246 (Figure 2). In
recipients who experienced acute graft-versus-host dis-
ease improved survival was also associated with DR15
negativity in the patients with HSCT from an unrelated
donor (P  .0086).
Similar analysis of 57 HLA identical related pedi-
atric recipients (aged 1-16 years) and 45 HLA identi-
cal unrelated pediatric recipients showed no signiﬁ-
cant ﬁndings, possibly reﬂecting different primary
disease proﬁles of younger patients.
To summarize, we agree that DR15-positive re-
cipients of related donor HSCT show improved over-
all survival, but believe that the reverse is true for
recipients of HSCT from unrelated donors. It is pos-
sible that this DR15 effect is most pronounced in
malignant conditions, as these observations could not
be reproduced in our pediatric population, which has
Figure 1. HSCT HLA identical adult related recipient and donor
pairs.
Figure 2. HSCT HLA identical adult unrelated recipient and
donor pairs.
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a high percentage of patients with heritable disorders
as their primary indication for HSCT. The reversal of
this association in patients receiving HSCT from un-
related donors may reﬂect increased disparity of genes
across the major histocompatibility complex between
a recipient and an unrelated donor. HLA-DR15 oc-
curs at a relatively high frequency worldwide (9.91%-
14.35%; 0.5%-54%) [1, 2], which suggests the exis-
tence of several ancestral haplotypes containing this
allele group. Matching ancestral haplotypes, and
hence, genes across the entire major histocompatibil-
ity complex, is guaranteed in related donation. In
unrelated donation, the likelihood of the donor and
recipient sharing an ancestral haplotype is extremely
low. Our data suggests that matching for additional
(non-HLA) genes within the major histocompatibility
complex contributes positively to HSCT outcome,
and further research to identify additional loci of in-
terest may enhance survival in unrelated HSCT.
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Unrelated Stem Cell
Transplantation after a
Reduced Intensity
Conditioning Regimen
Containing High-Dose
Thymoglobulin Leads to
Controllable Graft-
versus-Host Disease
Between April 2001 and November 2004, 28 pa-
tients with acute myeloid leukemia (AML), acute lym-
phoblastic leukemia (ALL), chronic myeloid leukemia
(CML), and myelodysplastic syndrome (MDS) had
allogeneic stem cell transplantation (SCT) from an
unrelated donor after a novel conditioning regimen con-
taining high-dose thymoglobulin (THY) (Table 1).
Fourteen patients had early disease: CML in ﬁrst
chronic phase (n  4), untreated MDS (n  5), or
acute leukemia in ﬁrst remission (n  5). Another 14
patients had advanced disease: CML in accelerated
(n  1), blastic (n  1) or 2nd chronic phase (n  2),
acute leukemia with primary induction failure (n  1),
in ﬁrst relapse (n  1), in 2nd remission (n  6), or in
3rd remission (n  2). All patient/donor pairs were
evaluated at the allele level for DRB1, but only 16 of
28 pairs had high-resolution typing for human leuko-
cyte antigen (HLA) class I antigens. With the tests
performed, 13 patient/donor pairs (46.4%) had HLA
antigen and/or allele mismatches, which are discrim-
inated in Table 1. Of the 7 females that donated, only
1 had a history of 2 previous pregnancies, whereas all
the others had not been pregnant. The patients trans-
planted with bone marrow received a lower cell dose
than the recipients of peripheral blood progenitor
cells (PBPC) (Table 1). The conditioning regimen
consisted of Ara-C 2 g/m2 on day 8, ﬂudarabine 30
mg/m2/day on days 8 to 4, THY 5 mg/kg/day
(Genzyme-Sangstat, Lyon, France) on days9 to5,
and melphalan 70 mg/m2/day on days 3 and 2.
Although THY was scheduled to be administered as a
12-hour infusion, 26 of 28 patients received the
planned dose over 24 hours because of toxicity. All
patients received prophylactic clemastine and pred-
nisolone 2 mg/kg/day on days 9 to 5 (1 mg/kg
prior to the administration of THY and 1 mg/kg in
the bag with THY), as previously described [1].
Patients with signiﬁcant THY toxicity also received
intravenous ranitidine. Graft-versus-host-disease
(GVHD) prophylaxis consisted of mycophenolate
mofetil 1 g every 12 hours plus cyclosporine A at
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